💡Just released Practice changing study in NEJM👉 Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. PFS DV vs chemo (median, 13.1 vs. 6.5 months; Overall survival DV vs Chemo (31.5 vs. 16.9 months;) objective response was DV 76.1% (95% CI, 70.3

An insightful story about AVPC by @aaparicioMD: how to interpret the molecular alterations and how we’ve been treating them @MDAndersonNews #ESMO25

Presidential EVP from KN905 in MIBC at #ESMO25 with incredibly strong data. PathCR of 57%! EFS and OS positive, a game changing study. ??? continuation of treatment with EV in those with pCR? Is cisplatin candidacy still relevant for MIBC? Ideal bladder sparing approach next?

Congratulations to @OncHahn, @JadChahoud and the entire team on completing this randomized investigator-initiated multicenter trial. Many thought it was impossible for such a comparison to be completed but you turned it into reality. @neerajaiims @PGrivasMDPhD @montypal

Our poster assessing prognostic scores in 1L EVP pts. Belmont score: liver mets, ECOG >0, and Hgb<10 was best for predicting OS/PFS . Thanks to UNITE @koshkin85 for this opportunity and incredible mentorship by @DocMattCampbell and @OAlhalabiMD

Excited to see LenCabo published concomitant in @Annals_Oncology Plan to post a full tweetorial summarizing our results later @PavlosMsaouel

Very proud of @CYJiangMD for her great poster at #ESMO25 with prognostic scores for EVP treated patients from UNITE. Bellmunt criteria was the best to differentiate PFS/OS. Good for strata on front line mUC studies comparing to EVP. Great teamwork across centers. @OAlhalabiMD

Congrats to Prof Camilo Jimenez @MDAndersonNews for presenting Ph2 belzutifan in advanced pheo/para with DCR of 80% median PFS nearly 2 years now published in @NEJM first targeted therapy FDA approved in this rare cancer type #ESMO25

Congrats @OncHahn for the great presentation of the LenCabo study #ESMO25 now published in Annals of Oncology. Len/EV with significantly higher PFS than cabozantinib in IO experienced patients with mccRCC

First trial of PD1/VEGF bispecific in #kidneycancer just activated today and is @NazliDizman’s trial design project during her @MDAndersonNews heme/onc fellowship 🤓 👉 https://t.co/F2ryVQ8zyV @brian_rini @montypal @OncHahn @OAlhalabiMD @DocMattCampbell @ChadTangMD @SGoswamiMDPhD

Tremendously enjoyed working with @Shounak_Gupta et al on this contemporary update of #RenalMedullaryCarcinoma pathology, pathophysiology, differential diagnosis & management. #kidneycancer #rarecancers #endRMC

Surreal to be completing training in oncology, 14 years after beginning the journey as a freshman in college diagnosed with testicular cancer. I owe so much to my doctors, Dr. Ahmed and Dr. Einhorn, who showed me what it meant to treat patients (and people) with compassion

👇Latest treatment & research updates on #RenalMedullaryCarcinoma. #endRMC #RareCancers #kidneycancer

White Coat Ceremony for my upcoming Internal Medicine Residency at Baylor College of Medicine @BCM_InternalMed - so grateful and blessed! 🙏

We have a couple of years before she gets to making her own videos advocating for #RCC 🧡. Thanks for all you do @KidneyCancer 👏🏻👏🏻

🎉 One of our FAVORITE events of the year, moving for 81’ in beautiful Hermann Park #Houston for the KCA’s 81K Fundraising Challenge! Thank you @DocMattCampbell for leading our #BoneMets Team @MDAndersonNews; KCA leadership @GEVaughan1 & team for organizing this event!

Great start to the weekend with @KidneyCancer 81K Houston walk with @MDAndersonNews in honor of those who will diagnosed with kidney cancer this year. Appreciate everyone who came out and walked in the heat @mjmoussa_ @ED_PhD_ @PavlosMsaouel and the bone mets lab.

🧵1/ T cells have deservedly been in the🔦for #cancer #immunotherapy, but other engineered cell therapies are now📈. What mediates NK cell exhaustion remains an important unanswered❓. 📄Link: https://t.co/dQIK4fVkxO I’m so thrilled🥳to share our work out now🚨@Nature

@CYJiangMD is doing some impressive work on MTAP loss in bladder cancer. Come check it out. @MDAndersonNews #ASCO25 #endcancer